Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HYDROCHLOROTHIAZIDE & TRIAMTERENE

All products: general benefit

Other products in the same Health Canada class (C03EA) — coverage varies; not interchangeable

  • Amiloride + hydrochlorothiazide (Moduret): general benefit, Not a benefit
  • Hydrochlorothiazide + spironolactone (Aldactazide-25): general benefit, Not a benefit

Apo-Triazide · DIN 00441775 · 25mg & 50mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Triazide · DIN 00441775 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.0608 Health Canada: Marketed since 1984-12-31 · brand APO-TRIAZIDE · ATC C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS, C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS · form Tablet · route Oral · ingredients TRIAMTERENE 50 MG, HYDROCHLOROTHIAZIDE 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Triazide: Formulary list price $0.0608/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0608 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5672 · Verify on the e-Formulary ↗ (DIN 00441775)

Source record
DIN 00441775: Apo-Triazide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800025; group id 563; item number 1506; lccId None; manufacturer id APX Source form: Tab; strength: 25mg & 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0608; ministry $0.0608 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00441775 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5672
Interchangeable products
Dyazide · DIN 01919547 · not recorded Teva-Triamterene/HCTZ · DIN 00532657 · $0.0608
Shortage status: resolved shortage (ended 2024-04-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00441775
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, INDAPAMIDE 40:28 Diuretics

AMILORIDE HCL & HYDROCHLOROTHIAZIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications APO-TRIAZIDE (Triamterene and Hydrochlorothiazide) is indicated in the maintenance therapy of: • Patients with edema associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome; also in steroid induced edema and idiopathic edema. • Patients with mild to moderate hypertension in those patients who have developed hypokalemia while on thiazide-like diuretics alone, and in those patients in whom potassium depletion is considered especially dangerous (e.g. digitalized patients). Medical opinion is not unanimous regarding the incidence and/or clinical significance of hypokalemia occurring among hypertensive patients treated with thiazide-like diuretics alone, and concerning the use of potassium-sparing combinations as routine therapy in hypertension. Fixed-dose combination drugs are not indicated for initial therapy. Patients should be titrated on the individual drugs. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. If during maintenance therapy dosage adjustment is necessary it is advisable to us… https://pdf.hres.ca/dpd_pm/00085869.PDF PM date: 2026-08-25 Source product: APO-TRIAZIDE; DIN 00441775; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.